Log in

Cyclerion Therapeutics Stock Price, News & Analysis (NASDAQ:CYCN)

$8.67
+0.20 (+2.36 %)
(As of 10/13/2019 04:00 PM ET)
Today's Range
$8.21
Now: $8.67
$9.33
50-Day Range
$8.29
MA: $10.80
$14.54
52-Week Range
$7.83
Now: $8.67
$21.00
Volume52,520 shs
Average Volume119,770 shs
Market Capitalization$237.73 million
P/E RatioN/A
Dividend YieldN/A
BetaN/A
There is no company description available for Cyclerion Therapeutics Inc.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CYCN
CUSIPN/A
CIKN/A
Phone857-327-8778

Debt

Price-To-Earnings

Sales & Book Value

Annual SalesN/A

Profitability

Miscellaneous

EmployeesN/A
Market Cap$237.73 million
Next Earnings Date11/11/2019 (Estimated)
OptionableNot Optionable

Receive CYCN News and Ratings via Email

Sign-up to receive the latest news and ratings for CYCN and its competitors with MarketBeat's FREE daily newsletter.


Cyclerion Therapeutics (NASDAQ:CYCN) Frequently Asked Questions

What is Cyclerion Therapeutics' stock symbol?

Cyclerion Therapeutics trades on the NASDAQ under the ticker symbol "CYCN."

How were Cyclerion Therapeutics' earnings last quarter?

Cyclerion Therapeutics Inc (NASDAQ:CYCN) announced its earnings results on Monday, August, 12th. The company reported ($1.18) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.84) by $0.34. The firm earned $1.63 million during the quarter. View Cyclerion Therapeutics' Earnings History.

When is Cyclerion Therapeutics' next earnings date?

Cyclerion Therapeutics is scheduled to release their next quarterly earnings announcement on Monday, November 11th 2019. View Earnings Estimates for Cyclerion Therapeutics.

What is the consensus analysts' recommendation for Cyclerion Therapeutics?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cyclerion Therapeutics in the last year. There are currently 1 hold rating for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Cyclerion Therapeutics.

Has Cyclerion Therapeutics been receiving favorable news coverage?

News headlines about CYCN stock have trended negative on Sunday, InfoTrie reports. InfoTrie identifies negative and positive news coverage by reviewing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores nearest to five being the most favorable. Cyclerion Therapeutics earned a daily sentiment score of -2.6 on InfoTrie's scale. They also gave headlines about the company a news buzz of 10.0 out of 10, indicating that recent news coverage is extremely likely to have an effect on the company's share price in the next few days. View News Stories for Cyclerion Therapeutics.

Are investors shorting Cyclerion Therapeutics?

Cyclerion Therapeutics saw a increase in short interest in the month of September. As of September 30th, there was short interest totalling 1,230,000 shares, an increase of 10.8% from the August 30th total of 1,110,000 shares. Based on an average daily trading volume, of 109,700 shares, the days-to-cover ratio is currently 11.2 days. Currently, 4.7% of the company's stock are short sold. View Cyclerion Therapeutics' Current Options Chain.

Who are some of Cyclerion Therapeutics' key competitors?

What other stocks do shareholders of Cyclerion Therapeutics own?

How do I buy shares of Cyclerion Therapeutics?

Shares of CYCN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cyclerion Therapeutics' stock price today?

One share of CYCN stock can currently be purchased for approximately $8.67.

How big of a company is Cyclerion Therapeutics?

Cyclerion Therapeutics has a market capitalization of $237.73 million. View Additional Information About Cyclerion Therapeutics.

What is Cyclerion Therapeutics' official website?

The official website for Cyclerion Therapeutics is http://www.cyclerion.com/.

How can I contact Cyclerion Therapeutics?

Cyclerion Therapeutics' mailing address is 301 BINNEY STREET, CAMBRIDGE MA, 02142. The company can be reached via phone at 857-327-8778 or via email at [email protected]


MarketBeat Community Rating for Cyclerion Therapeutics (NASDAQ CYCN)

Community Ranking:  1.8 out of 5 (star)
Outperform Votes:  10 (Vote Outperform)
Underperform Votes:  18 (Vote Underperform)
Total Votes:  28
MarketBeat's community ratings are surveys of what our community members think about Cyclerion Therapeutics and other stocks. Vote "Outperform" if you believe CYCN will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CYCN will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 10/13/2019 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel